MDM4 and cancer: In 2010, Yan’s group described the use of benzofuroxan derivative XI-006 (NSC207895) as an inhibitor of the MDMX expression in cancer cells; the treatment of MCF-7 cells with this compound activated p53, resulting in a higher expression of proapoptotic genes [180].